Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $486.40 million. The enterprise value is $404.04 million.
Important Dates
The last earnings date was Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 58.53 million shares outstanding. The number of shares has increased by 7.64% in one year.
| Current Share Class | 46.34M |
| Shares Outstanding | 58.53M |
| Shares Change (YoY) | +7.64% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | 16.43% |
| Owned by Institutions (%) | 58.68% |
| Float | 36.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.85 |
| Forward PS | 2.64 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.67.
| Current Ratio | 4.88 |
| Quick Ratio | 4.70 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4,156.53 |
Financial Efficiency
Return on equity (ROE) is -57.76% and return on invested capital (ROIC) is -21.20%.
| Return on Equity (ROE) | -57.76% |
| Return on Assets (ROA) | -16.99% |
| Return on Invested Capital (ROIC) | -21.20% |
| Return on Capital Employed (ROCE) | -33.17% |
| Revenue Per Employee | $284,673 |
| Profits Per Employee | -$566,037 |
| Employee Count | 834 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -422,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.70% in the last 52 weeks. The beta is 1.29, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -72.70% |
| 50-Day Moving Average | 7.20 |
| 200-Day Moving Average | 8.97 |
| Relative Strength Index (RSI) | 58.67 |
| Average Volume (20 Days) | 1,148,661 |
Short Selling Information
The latest short interest is 11.63 million, so 19.87% of the outstanding shares have been sold short.
| Short Interest | 11.63M |
| Short Previous Month | 11.40M |
| Short % of Shares Out | 19.87% |
| Short % of Float | 31.68% |
| Short Ratio (days to cover) | 7.97 |
Income Statement
In the last 12 months, DNA had revenue of $237.42 million and -$472.08 million in losses. Loss per share was -$8.92.
| Revenue | 237.42M |
| Gross Profit | 190.02M |
| Operating Income | -390.71M |
| Pretax Income | -897.68M |
| Net Income | -472.08M |
| EBITDA | -325.20M |
| EBIT | -390.71M |
| Loss Per Share | -$8.92 |
Full Income StatementBalance Sheet
The company has $516.92 million in cash and $434.56 million in debt, giving a net cash position of $82.36 million or $1.41 per share.
| Cash & Cash Equivalents | 516.92M |
| Total Debt | 434.56M |
| Net Cash | 82.36M |
| Net Cash Per Share | $1.41 |
| Equity (Book Value) | 647.43M |
| Book Value Per Share | 11.84 |
| Working Capital | 448.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$281.85 million and capital expenditures -$63.45 million, giving a free cash flow of -$345.30 million.
| Operating Cash Flow | -281.85M |
| Capital Expenditures | -63.45M |
| Free Cash Flow | -345.30M |
| FCF Per Share | -$5.90 |
Full Cash Flow StatementMargins
Gross margin is 80.04%, with operating and profit margins of -164.57% and -198.84%.
| Gross Margin | 80.04% |
| Operating Margin | -164.57% |
| Pretax Margin | -199.02% |
| Profit Margin | -198.84% |
| EBITDA Margin | -136.97% |
| EBIT Margin | -164.57% |
| FCF Margin | n/a |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.64% |
| Shareholder Yield | -7.64% |
| Earnings Yield | -97.05% |
| FCF Yield | -70.99% |
Dividend DetailsAnalyst Forecast
The average price target for DNA is $17.25, which is 107.58% higher than the current price. The consensus rating is "Sell".
| Price Target | $17.25 |
| Price Target Difference | 107.58% |
| Analyst Consensus | Sell |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 0.025:1.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.025:1 |
Scores
DNA has an Altman Z-Score of -6.08 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.08 |
| Piotroski F-Score | 2 |